Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen

NCT00051844

Last updated date
Study Location
Pfizer Investigational Site
Beverly Hills, California, 90211, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Human Immunodeficiency Virus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female at least 18 years old

- HIV RNA level >1000 copies/mL at screening

- CD4 >50 cells/uL at screening

- Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen

- Patient has adequate hematology tests (absolute neutrophil count >1000/uL, Platelets>75,000uL, hemoglobin 9g/L)

- Patient has adequate renal function (serum creatinine of <1.5 upper limit of normal)

- Patient has adequate liver function (AST, ALT, and bilirubin < 2.5 upper limit of normal)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Previous use of protease inhibitors (except if patient has short duration of PI and
was switched for tolerability reasons when viral load was <50 copies) This exception
does not include Viracept


- Women who are pregnant or lactating

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Human Immunodeficiency VirusCapravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen NCT00051844
  1. Beverly Hills, California
  2. Long Beach, California
  3. Newport Beach, California
  4. San Francisco, California
  5. San Francisco, California
  6. West Hollywood, California
  7. Fort Lauderdale, Florida
  8. Miami, Florida
  9. Safety Harbor, Florida
  10. Tampa, Florida
  11. Atlanta, Georgia
  12. Jonesboro, Georgia
  13. Tucker, Georgia
  14. Chicago, Illinois
  15. Wichita, Kansas
  16. Jackson, Mississippi
  17. Brooklyn, New York
  18. New York, New York
  19. Stony Brook, New York
  20. Huntersville, North Carolina
  21. Winston-Salem, North Carolina
  22. Akron, Ohio
  23. Cincinnati, Ohio
  24. Portland, Oregon
  25. Portland, Oregon
  26. Philadelphia, Pennsylvania
  27. Austin, Texas
  28. Dallas, Texas
  29. Galveston, Texas
  30. Houston, Texas
  31. Lyon, Cedex 02
  32. Paris, Cedex 10
  33. Lyon, Cedex 3
  34. Nantes,
  35. Ulm, Bavaria
  36. Brescia,
  37. Milano,
  38. Milano,
  39. Roma,
  40. Cape Town,
  41. Cape Town,
  42. Johannesburg,
  43. Johannesburg,
  44. Johannesburg,
  45. Pietermaritzburg,
  46. Port Elizabeth,
  47. Pretoria North,
  48. Soweto,
  49. Baracaldo, Bilbao, Vizcaya
  50. Bilbao, Vizcaya
  51. Barcelona,
  52. Cordoba,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Human Immunodeficiency VirusSafety And Efficacy Study Of CP-675,206 In HIV-Infected Patients NCT00488995
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen
Official Title  ICMJE A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen
Brief Summary This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Human Immunodeficiency Virus
Intervention  ICMJE Drug: Capravirine
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 9, 2011)
179
Original Enrollment  ICMJE
 (submitted: June 23, 2005)
150
Actual Study Completion Date  ICMJE November 2004
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female at least 18 years old
  • HIV RNA level >1000 copies/mL at screening
  • CD4 >50 cells/uL at screening
  • Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen
  • Patient has adequate hematology tests (absolute neutrophil count >1000/uL, Platelets>75,000uL, hemoglobin 9g/L)
  • Patient has adequate renal function (serum creatinine of <1.5 upper limit of normal)
  • Patient has adequate liver function (AST, ALT, and bilirubin < 2.5 upper limit of normal)

Exclusion Criteria:

  • Previous use of protease inhibitors (except if patient has short duration of PI and was switched for tolerability reasons when viral load was <50 copies) This exception does not include Viracept
  • Women who are pregnant or lactating
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France,   Germany,   Italy,   South Africa,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00051844
Other Study ID Numbers  ICMJE A4311002
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Pfizer
Verification Date May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP